Home/Pipeline/DT-DEC01

DT-DEC01

Duchenne Muscular Dystrophy (DMD)

Phase 1Active (Dose Escalation)

Key Facts

Indication

Duchenne Muscular Dystrophy (DMD)

Phase

Phase 1

Status

Active (Dose Escalation)

Company

Dystrogen Therapeutics

About Dystrogen Therapeutics

Dystrogen Therapeutics is developing a first-in-class chimeric cell therapy platform with broad applications in genetic and degenerative disorders. Its core technology involves fusing donor and recipient cells to create 'Dystrophin Expressing Chimeric (DEC)' cells that evade immune rejection, eliminating the need for immunosuppression. The company is initially focused on Duchenne Muscular Dystrophy, with a Phase 1 trial underway, and has preclinical programs targeting sarcopenia, age-related muscle loss, and neurodegenerative diseases. Dystrogen's approach represents a potentially paradigm-shifting alternative to gene therapy and other advanced modalities.

View full company profile

Therapeutic Areas

Muscular Dystrophy Neuromuscular Diseases Rare Diseases Sarcopenia Neurodegenerative Diseases

Other Duchenne Muscular Dystrophy (DMD) Drugs

Drug	Company	Phase	Status
Skeletal Muscle Regeneration Program	IPS HEART	Pre-clinical	Active
KYMBEE (deflazacort)	Upsher-Smith	Approved	Active
ALY688ER	Allysta Pharmaceuticals	Phase 1	Active
AVGN7 + AVGND	AAVogen	Pre-clinical	Active
Myomatrix Stabilization Program	Strykagen	Preclinical	Active
RIPPLE™ (implied)	SonoThera	Preclinical	Active
Vamorolone (AGAMREE)	ReveraGen BioPharma	Approved	Active
AGAMREE (vamorolone)	Catalyst Pharmaceuticals	Marketed	Commercial; Long-term safety monitored via SUMMIT Registry
EDG-5506	Edgewise Therapeutics	Phase 2	Active
ELEVIDYS (delandistrogene moxeparvovec-rokl)	Sarepta Therapeutics	Marketed / Phase 3	FDA Accelerated Approval; Confirmatory trial ongoing
SRP-5051 (vesleteplirsen)	Sarepta Therapeutics	Phase 2	Active (Next-gen PPMO)
EXONDYS 51 (eteplirsen)	Sarepta Therapeutics	Marketed	FDA Approved